Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber ...
In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...
Vevye will be included in key formularies of major plan sponsors, covering over 25 million Medicare Part D beneficiaries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback